Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | protein-tyrosine phosphatase | 0.035 | 0.8414 | 0.8414 |
Schistosoma mansoni | ap endonuclease | 0.0037 | 0.0099 | 0.0118 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.028 | 0.0332 |
Schistosoma mansoni | ap endonuclease | 0.0037 | 0.0099 | 0.0118 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0037 | 0.0099 | 0.0099 |
Loa Loa (eye worm) | hypothetical protein | 0.0048 | 0.0405 | 0.0405 |
Onchocerca volvulus | Putative organic anion transporter | 0.0409 | 1 | 0.5 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0037 | 0.0099 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0037 | 0.0099 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0037 | 0.0099 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0037 | 0.0099 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0037 | 0.0099 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0037 | 0.0099 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0037 | 0.0099 | 0.5 |
Echinococcus granulosus | tyrosine protein phosphatase non receptor type | 0.035 | 0.8414 | 1 |
Schistosoma mansoni | protein tyrosine phosphatase non-receptor type nt1 | 0.035 | 0.8414 | 1 |
Brugia malayi | Protein-tyrosine phosphatase containing protein | 0.035 | 0.8414 | 0.8414 |
Loa Loa (eye worm) | hypothetical protein | 0.0409 | 1 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0048 | 0.0405 | 0.0405 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.028 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0048 | 0.0405 | 0.0405 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.028 | 0.0217 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0037 | 0.0099 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.028 | 1 |
Echinococcus multilocularis | tyrosine protein phosphatase non receptor type | 0.035 | 0.8414 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0037 | 0.0099 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.028 | 1 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0037 | 0.0099 | 0.0099 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0037 | 0.0099 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.028 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.028 | 0.0217 |
Toxoplasma gondii | exonuclease III APE | 0.0037 | 0.0099 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0037 | 0.0099 | 0.5 |
Brugia malayi | hypothetical protein | 0.0043 | 0.028 | 0.028 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0037 | 0.0099 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0048 | 0.0405 | 0.0405 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0037 | 0.0099 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.028 | 0.0332 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 10.3225 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 14.7157 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 23.7781 uM | PubChem BioAssay. qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 23.9341 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. Inhibitors of USP1/UAF1: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | ||
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.